Matches in UGent Biblio for { <https://biblio.ugent.be/publication/2137716#aggregation> ?p ?o. }
Showing items 1 to 40 of
40
with 100 items per page.
- aggregation classification "A1".
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation creator person.
- aggregation date "2011".
- aggregation format "application/pdf".
- aggregation hasFormat 2137716.bibtex.
- aggregation hasFormat 2137716.csv.
- aggregation hasFormat 2137716.dc.
- aggregation hasFormat 2137716.didl.
- aggregation hasFormat 2137716.doc.
- aggregation hasFormat 2137716.json.
- aggregation hasFormat 2137716.mets.
- aggregation hasFormat 2137716.mods.
- aggregation hasFormat 2137716.rdf.
- aggregation hasFormat 2137716.ris.
- aggregation hasFormat 2137716.txt.
- aggregation hasFormat 2137716.xls.
- aggregation hasFormat 2137716.yaml.
- aggregation isPartOf urn:issn:0306-5251.
- aggregation language "eng".
- aggregation rights "I have transferred the copyright for this publication to the publisher".
- aggregation subject "Medicine and Health Sciences".
- aggregation title "Pharmacokinetics of two formulations of omeprazole administered through a gastrostomy tube in patients with severe neurodevelopmental problems".
- aggregation abstract "AIMS Omeprazole is often administered through a gastrostomy tube as either (i) a Multiple Unit Pellet System (MUPS (R)) tablet disintegrated in water (MUPS (R) formulation), or (ii) a suspension in 8.4% sodium bicarbonate (suspension formulation). This bioavailability study evaluates this practice in tube-fed patients with severe neurodevelopmental problems. METHODS Nonblinded, two-phase cross-over trial. RESULTS In seven of 10 patients, bioavailability was higher for the suspension formulation than for the MUPS (R) formulation. Median (90% confidence interval) area under the plasma concentration-time curve ratio (MUPS (R) over suspension) was 0.5 (0.06-2.37). CONCLUSIONS In this population, omeprazole MUPS (R) formulation has no apparent advantage over the more easily administered suspension formulation.".
- aggregation authorList BK447644.
- aggregation endPage "996".
- aggregation issue "6".
- aggregation startPage "990".
- aggregation volume "72".
- aggregation aggregates 2137727.
- aggregation isDescribedBy 2137716.
- aggregation similarTo j.1365-2125.2011.04038.x.
- aggregation similarTo LU-2137716.